Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRD5A2 | P31213 | 1/20 | 0.34 |
| ▸ | F3 | P13726 | 5/20 | 0.33 |
| ▸ | F2 | P00734 | 4/20 | 0.33 |
| ▸ | KDR | P35968 | 7/20 | 0.32 |
| ▸ | BRAF | P15056 | 6/20 | 0.32 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.31 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12763879 | 0.92 | KDR (0.34) | KDRBRAFPTK2SCN5ASCN9A | |
| SCHEMBL12763835 | 0.89 | KDR (0.33) | SRD5A2F3F2KDRBRAF | |
| SCHEMBL12763878 | 0.89 | KDR (0.32) | SRD5A2F3F2KDRBRAF | |
| SCHEMBL12763894 | 0.89 | CACNA1G (0.33) | F3F2KDRBRAFPTGER4 | |
| SCHEMBL12763875 | 0.88 | NR1H2 (0.36) | F3F2KDRBRAFPTK2 | |
| SCHEMBL12763869 | 0.88 | KDR (0.32) | SRD5A2F3F2KDRBRAF | |
| SCHEMBL12763896 | 0.88 | TRPM8 (0.33) | SRD5A2F3F2KDRBRAF | |
| SCHEMBL12837382 | 0.87 | KDR (0.34) | SRD5A2F3F2KDRBRAF | |
| SCHEMBL12763916 | 0.86 | NR1H2 (0.32) | SRD5A2F3F2KDRBRAF | |
| SCHEMBL13044901 | 0.86 | MGLL (0.39) | F3SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| US-7897622-B2 | 2-amido-5-oxo/thio-benzoic acid derivatives; hepatitis C virus infection; synergistic with another inhibitor of HCV polymerase or immunomodulatory agent such as interferons | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-03-01 | — | — | US | disclosed |
| WO-2008019477-A1 | VIRAL POLYMERASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
| US-20080045516-A1 | Viral Polymerase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080045516-A1 | Viral Polymerase Inhibitors | POLR2A, POLR2H, POLR2E | SRD5A2 1559/4885F3 212/4885F2 287/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.